CLINICAL_TRIALS
trial_result
· 2023-09-22
Clinical Trial Update: A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) [Phase 2]
Summary
Phase 2 trial of Treprostinil Palmitil Inhalation Powder (TPIP) for pulmonary arterial hypertension has been terminated; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Insmed Incorporated | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2023-09-22